Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05617040 · ClinicalTrials.gov registry record · Phase 1
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
A Phase 1 study, sponsored by Barinthus Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05617040 is a Phase 1 study that was terminated before completion, run by Barinthus Biotherapeutics. The registered enrollment target is 22 participants.
The verdict
NCT05617040, a Phase 1 study, was terminated before completion, sponsored by Barinthus Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
Interventions
- BIOLOGICAL ChAdOx1-PCAQ
- BIOLOGICAL MVA-PCAQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05617040
The ClinicalTrials.gov registry entry for NCT05617040 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barinthus Biotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ChAdOx1-PCAQ is the first listed.
NCT05617040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05617040 about?
NCT05617040 is a clinical study titled "Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer". This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
What is the current status of trial NCT05617040?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-01-30. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05617040?
The interventions under investigation include: ChAdOx1-PCAQ (BIOLOGICAL), MVA-PCAQ (BIOLOGICAL).
Who is sponsoring clinical trial NCT05617040?
This trial is sponsored by Barinthus Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.